243 related articles for article (PubMed ID: 18775199)
1. Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention.
Gumina RJ; Yang EH; Sandhu GS; Prasad A; Bresnahan JF; Lennon RJ; Rihal CS; Holmes DR; Singh M
Mayo Clin Proc; 2008 Sep; 83(9):995-1001. PubMed ID: 18775199
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
5. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality.
Witkowski A; Maciejewski P; Wasek W; Malek LA; Niewada M; Kaminski B; Drzewiecki J; Kosmider M; Kubica J; Ruzyllo W; Peruga JZ; Dudek D; Opolski G; Dobrzycki S; Gil RJ;
Eur Heart J; 2009 Jul; 30(14):1736-43. PubMed ID: 19376786
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
[TBL] [Abstract][Full Text] [Related]
7. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Feldman DN; Wong SC; Bergman G; Minutello RM
J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
[TBL] [Abstract][Full Text] [Related]
8. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
Chan AW; Moliterno DJ; Berger PB; Stone GW; DiBattiste PM; Yakubov SL; Sapp SK; Wolski K; Bhatt DL; Topol EJ;
J Am Coll Cardiol; 2003 Oct; 42(7):1188-95. PubMed ID: 14522478
[TBL] [Abstract][Full Text] [Related]
9. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
Karha J; Gurm HS; Rajagopal V; Fathi R; Bavry AA; Brener SJ; Lincoff AM; Ellis SG; Bhatt DL
Am J Cardiol; 2006 Oct; 98(7):906-10. PubMed ID: 16996871
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.
Dörler J; Edlinger M; Alber HF; Altenberger J; Benzer W; Grimm G; Huber K; Pachinger O; Schuchlenz H; Siostrzonek P; Zenker G; Weidinger F;
Eur Heart J; 2011 Dec; 32(23):2954-61. PubMed ID: 21920970
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit with concomitant oral platelet therapy after coronary angiography and before ad hoc percutaneous coronary intervention.
Patel RA; White CJ
Mayo Clin Proc; 2008 Sep; 83(9):978-9. PubMed ID: 18775195
[No Abstract] [Full Text] [Related]
12. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
[TBL] [Abstract][Full Text] [Related]
13. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
[TBL] [Abstract][Full Text] [Related]
14. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials.
Pannu R; Andraws R
Crit Pathw Cardiol; 2008 Mar; 7(1):5-10. PubMed ID: 18458661
[TBL] [Abstract][Full Text] [Related]
15. Association of glycoprotein IIb/IIIa inhibitors and long-term survival following administration during percutaneous coronary intervention for acute myocardial infarction.
Berger JS; Brown DL
J Thromb Thrombolysis; 2006 Jun; 21(3):229-34. PubMed ID: 16683214
[TBL] [Abstract][Full Text] [Related]
16. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
[TBL] [Abstract][Full Text] [Related]
18. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
19. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Silva MA; Donovan JL; Gandhi PJ; Volturo GA
Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
[TBL] [Abstract][Full Text] [Related]
20. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
